ALNY up +1.02% percent Today $ALNY High is at 93.99 and the Low 89.50 with current volume of 98,082.
Recent News posted below.
Alnylam Pharmaceuticals ALNY other info.
http://investorshangout.com/Alnylam-Pharmaceu...LNY-53281/
ALNY Alnylam Pharmaceuticals Recent Headline News
Nasdaq stocks posting largest percentage decreases
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
VCYT: 6.75 (-0.02), ALNY: 89.30 (-0.82), RTRX: 9.55 (-0.35), VASC: 23.58 (-0.16), DGLY: 11.61 (+0.11)
Watch for Alnylam Pharmaceuticals to Potentially Rebound After Falling 9.27% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 4:53PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $89.88 to a high of $100.00. Yesterday, the shares fell 9.3%, which took the trading range below the 3-day low of $97.01 on volume of 908,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 89.30 (-0.82)
Alnylam Pharmaceuticals (ALNY) Weak On High Volume
at The Street - Fri Nov 14, 9:04AM CST
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate
ALNY: 89.30 (-0.82)
Alnylam reports results from Phase 2 revusiran trial
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:41AM CST
ALNY: 89.30 (-0.82)
Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients
Business Wire - Fri Nov 14, 5:00AM CST
--- After Five Weeks of Treatment, No Significant Changes in Exploratory Clinical Measurements Observed -
ALNY: 89.30 (-0.82)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 304.86 (-0.57), ALNY: 89.30 (-0.82), ILMN: 180.54 (+0.04), AMAG: 34.73 (+0.73)
Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections
Business Wire - Tue Nov 11, 7:00AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline. Specifically, in a presentation at the American Association for the Study of Liver Diseases (AASLD) meeting, the company announced it has added ALN-HDV, an RNAi therapeutic targeting the hepatitis delta viral (HDV) genome in development for the treatment of HDV infection. Further, it has added ALN-PDL, an RNAi therapeutic targeting hepatocyte-expressed programmed death ligand 1 (PD-L1) in development for the treatment of chronic liver infections. In addition, Alnylam continues to advance its ALN-HBV program, in development for the treatment of hepatitis B viral (HBV) infection; the company remains on track to select a Development Candidate (DC) by the end of the year and expects to file an investigational new drug (IND) application or IND equivalent around the end of 2015.
ALNY: 89.30 (-0.82)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 3.48% Rise
Comtex SmarTrend(R) - Mon Nov 10, 5:33PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $95.84 to a high of $99.87. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $97.19 on volume of 715,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 89.30 (-0.82)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 61.6% (ALNY)
Comtex SmarTrend(R) - Mon Nov 10, 12:24PM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 61.63% as of today's recent price of $99.17.
ALNY: 89.30 (-0.82)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST
AGTC: 22.60 (-0.45), BXE: 4.54 (-0.12), ROKA: 3.69 (+0.09), ALNY: 89.30 (-0.82), NCT: 4.77 (-0.08), SSRI: 5.21 (-0.04), ABCB: 25.60 (-0.10), OSIR: 13.31 (+0.26), XCO: 3.11 (-0.13), JDST: 21.11 (-0.45)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 304.86 (-0.57), ALNY: 89.30 (-0.82), ISIS: 48.40 (-0.61), OGXI: 2.20 (+0.02), TEVA: 57.60 (+0.53), RGLS: 16.94 (-0.26), GSK: 45.86 (+0.12), SNY: 47.33 (+0.65)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 89.30 (-0.82), MDCO: 25.00 (+0.53), SNY: 47.33 (+0.65)
Alnylam to Webcast Presentation at the Credit Suisse 2014 Healthcare Conference
Business Wire - Thu Nov 06, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 3:00 p.m. MST (5:00 p.m. EST) at the Arizona Biltmore in Phoenix, Arizona.
ALNY: 89.30 (-0.82)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 304.86 (-0.57), ALNY: 89.30 (-0.82), AMAG: 34.73 (+0.73)
Investing in Socially Responsible Companies: Alnylam Pharmaceuticals, Inc.
Selena Maranjian, The Motley Fool - Motley Fool - Thu Nov 06, 9:22AM CST
Source: Alnylam Pharmaceuticals. Being a socially responsible company is not a zero-sum game, where the more socially responsible you are, the worse your financial performance is, and vice versa. Profits don't go out the window when you treat the...
ALNY: 89.30 (-0.82)
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:12PM CST
ALNY: 89.30 (-0.82)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 89.30 (-0.82), AMGN: 158.64 (+0.96), SNY: 47.33 (+0.65), REGN: 403.28 (+8.08)
Alnylam beats Street 3Q forecasts
Automated Insights - Wed Nov 05, 5:04PM CST
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Wednesday reported a loss of $44 million in its third quarter.
ALNY: 89.30 (-0.82)
Alnylam Pharmaceuticals (ALNY) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
ALNY: 89.30 (-0.82)
Recent News posted below.
Alnylam Pharmaceuticals ALNY other info.
http://investorshangout.com/Alnylam-Pharmaceu...LNY-53281/
ALNY Alnylam Pharmaceuticals Recent Headline News
Nasdaq stocks posting largest percentage decreases
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
VCYT: 6.75 (-0.02), ALNY: 89.30 (-0.82), RTRX: 9.55 (-0.35), VASC: 23.58 (-0.16), DGLY: 11.61 (+0.11)
Watch for Alnylam Pharmaceuticals to Potentially Rebound After Falling 9.27% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 4:53PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $89.88 to a high of $100.00. Yesterday, the shares fell 9.3%, which took the trading range below the 3-day low of $97.01 on volume of 908,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 89.30 (-0.82)
Alnylam Pharmaceuticals (ALNY) Weak On High Volume
at The Street - Fri Nov 14, 9:04AM CST
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate
ALNY: 89.30 (-0.82)
Alnylam reports results from Phase 2 revusiran trial
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:41AM CST
ALNY: 89.30 (-0.82)
Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients
Business Wire - Fri Nov 14, 5:00AM CST
--- After Five Weeks of Treatment, No Significant Changes in Exploratory Clinical Measurements Observed -
ALNY: 89.30 (-0.82)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 304.86 (-0.57), ALNY: 89.30 (-0.82), ILMN: 180.54 (+0.04), AMAG: 34.73 (+0.73)
Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections
Business Wire - Tue Nov 11, 7:00AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline. Specifically, in a presentation at the American Association for the Study of Liver Diseases (AASLD) meeting, the company announced it has added ALN-HDV, an RNAi therapeutic targeting the hepatitis delta viral (HDV) genome in development for the treatment of HDV infection. Further, it has added ALN-PDL, an RNAi therapeutic targeting hepatocyte-expressed programmed death ligand 1 (PD-L1) in development for the treatment of chronic liver infections. In addition, Alnylam continues to advance its ALN-HBV program, in development for the treatment of hepatitis B viral (HBV) infection; the company remains on track to select a Development Candidate (DC) by the end of the year and expects to file an investigational new drug (IND) application or IND equivalent around the end of 2015.
ALNY: 89.30 (-0.82)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 3.48% Rise
Comtex SmarTrend(R) - Mon Nov 10, 5:33PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $95.84 to a high of $99.87. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $97.19 on volume of 715,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 89.30 (-0.82)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 61.6% (ALNY)
Comtex SmarTrend(R) - Mon Nov 10, 12:24PM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 61.63% as of today's recent price of $99.17.
ALNY: 89.30 (-0.82)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST
AGTC: 22.60 (-0.45), BXE: 4.54 (-0.12), ROKA: 3.69 (+0.09), ALNY: 89.30 (-0.82), NCT: 4.77 (-0.08), SSRI: 5.21 (-0.04), ABCB: 25.60 (-0.10), OSIR: 13.31 (+0.26), XCO: 3.11 (-0.13), JDST: 21.11 (-0.45)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 304.86 (-0.57), ALNY: 89.30 (-0.82), ISIS: 48.40 (-0.61), OGXI: 2.20 (+0.02), TEVA: 57.60 (+0.53), RGLS: 16.94 (-0.26), GSK: 45.86 (+0.12), SNY: 47.33 (+0.65)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 89.30 (-0.82), MDCO: 25.00 (+0.53), SNY: 47.33 (+0.65)
Alnylam to Webcast Presentation at the Credit Suisse 2014 Healthcare Conference
Business Wire - Thu Nov 06, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 3:00 p.m. MST (5:00 p.m. EST) at the Arizona Biltmore in Phoenix, Arizona.
ALNY: 89.30 (-0.82)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 304.86 (-0.57), ALNY: 89.30 (-0.82), AMAG: 34.73 (+0.73)
Investing in Socially Responsible Companies: Alnylam Pharmaceuticals, Inc.
Selena Maranjian, The Motley Fool - Motley Fool - Thu Nov 06, 9:22AM CST
Source: Alnylam Pharmaceuticals. Being a socially responsible company is not a zero-sum game, where the more socially responsible you are, the worse your financial performance is, and vice versa. Profits don't go out the window when you treat the...
ALNY: 89.30 (-0.82)
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:12PM CST
ALNY: 89.30 (-0.82)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 89.30 (-0.82), AMGN: 158.64 (+0.96), SNY: 47.33 (+0.65), REGN: 403.28 (+8.08)
Alnylam beats Street 3Q forecasts
Automated Insights - Wed Nov 05, 5:04PM CST
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Wednesday reported a loss of $44 million in its third quarter.
ALNY: 89.30 (-0.82)
Alnylam Pharmaceuticals (ALNY) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
ALNY: 89.30 (-0.82)
